To describe primary immunodeficiencies caused by gain-of-function (GOF) mutations of signal transducer and activator of transcription (STAT) genes, a group of genetically determined disorders characterized by susceptibility to infections and, in many cases, autoimmune manifestations.
INTRODUCTION
Signal transducer and activator of transcription (STAT) family members are transcription factors with a key role in the regulation of cellular response to interferons (IFNs), cytokines, growth factors and hormones. After extracellular stimulation, Janus kinase (JAK) activation leads to tyrosine phosphorylation of cytoplasmic STAT proteins, followed by homodimerization or heterodimerization with other phosphorylated STAT family members. STAT homodimers or heterodimers translocate into the nucleus where they bind to selected promoter elements of designated genes activating complex transcription programmes. STAT1 and STAT3 are both targets of either loss-offunction (LOF) or gain-of-function (GOF) mutations. STAT1 and STAT3 LOF mutations are associated with mycobacterial and/or viral infections or with the autosomal-dominant hyperimmunoglobulin E syndrome (AD-HIES), respectively. In contrast, STAT1 and STAT3 GOF mutations can both result in multisystem autoimmune disease and, in the case of STAT1, with chronic mucocutaneous candidiasis
SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION1 GAIN OF FUNCTION MUTATIONS
STAT1 GOF phenotype was included in the Online Mendelian Inheritance in Man (OMIM) as Immunodeficiency 31C (OMIM 614162) and displays an autosomal-dominant inheritance pattern. Although there is great variability in the clinical manifestations, the vast majority of patients with STAT1 GOF mutations experience chronic mucocutaneous candidiasis (CMC) and recurrent lower respiratory tract bacterial infections, whereas viral infections, autoimmune, inflammatory and vascular diseases, or tumors are less common. These clinical features contrast with STAT1 LOF mutations (Immunodeficiency 31B; OMIM 613796), many of which have an autosomal recessive inheritance pattern and a distinct clinical syndrome of severe mycobacterial and viral infections, particularly with herpesviruses.
In a recent study that has enrolled 274 patients with heterozygous GOF mutations, 98% had CMC with a median age at onset of 1 year, 74% had bacterial infections with recurrent lobar pneumonia, bronchitis or interstitial pneumonia (47%), mainly caused by Streptococcus pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae and Staphylococcus aureus [2 && ]. Recurrence of pulmonary exacerbations frequently leads to chronic lung disease with an obstructive component as shown by spirometry and progression to bronchiectasis in childhood [3] . ]. Systemic or atypical viral infections, mainly caused by herpes simplex virus and varicella-zoster virus, were observed in 38% of patients, but persistent molluscum contagiosum, warts, cytomegalovirus, Epstein-Barr virus and debilitating ecthyma due to parapoxvirus (Orf) infection were also reported in patients with STAT1 GOF mutations [3, [6] [7] [8] [9] . In addition, some of these patients can develop hemophagocytic lymphohistiocytosis with poor outcome [10 & ]. In one patient cohort, autoimmune diseases were observed in 37% of cases; with endocrinopathy (i.e. hypothyroidism and type 1 diabetes mellitus) the most common manifestations, but autoimmune cytopenias, cutaneous autoimmune manifestations, including vitiligo, alopecia or psoriasis, and systemic lupus erythematosus also reported [2 && ,3,5] . Autoantibodies were detected in 42% of patients tested, and were more frequently associated with clinical autoimmune manifestations (65%). However, in 20% of patients, autoantibodies were detectable in the absence of symptoms.
Absolute lymphocyte counts are often in the lower range in childhood, but some patients can present frank lymphopenia with significant reduc-
þ and CD8 þ T-cell subsets often evident by adulthood [3, 7] . Some of these patients present with a combined immunodeficiency (CID)-like phenotype characterized by overwhelming viral infections, mostly herpes viruses with possible lethal outcome [3, 11] .
Heterozygous missense mutations of STAT1 mutations have been identified in about half of patients with susceptibility to mucocutaneous fungal infections. They are located in the coiled-coiled or in the DNA binding domain of STAT1 and cause a signal-induced increase in the levels of tyrosine
KEY POINTS
Patients with heterozygous STAT1 GOF mutations usually present with mucocutaneous candidiasis and lower respiratory tract infections, but can develop severe disease with autoimmune manifestations, invasive infections, aneurysms or cancer.
Patients with heterozygous STAT3 GOF can display multiple autoimmune diseases from childhood, including autoimmune enteropathy, type 1 diabetes mellitus, autoimmune interstitial lung disease and autoimmune cytopenias; lymphoproliferative disorders, short stature and recurrent/severe infections are also common.
Disease treatment varies widely depending on the type of infections and/or the particular autoimmune phenomenon.
Targeted treatment with drugs interfering with the induction of STAT1 signaling, for example ruxolitinib, a JAK inhibitor, for STAT1 GOF, or, which inhibit specific cytokine activity, for example anti-IL-6 receptor in STAT3 GOF, can be used to control the disease activity in selected patients.
phosphorylated STAT1 (pSTAT1) by impairing nuclear dephosphorylation [5, 12] (Fig. 1) . In addition, increased levels of pSTAT1 result in upregulation of STAT1 mRNA and protein in primary resting natural killer (NK) and T cells of STAT1 GOF patients, suggesting that activation of STAT1 signaling pathway can further amplify cell response to type I and type II IFNs in these patients [13 && ]. Increased cellular response to IFN-a/b, IFN-g and interleukin-27 is associated with an impairment in the development of Th17 cells (CD4 T cells producing IL-17), a cell type that plays an important role in controlling mucosal and cutaneous candidal infections and, potentially, other fungal infections, for example Aspergillus spp. Th17 cells differentiation from naive T cells is strictly dependent on STAT3 signaling upon stimulation with IL-1b, IL-6 and IL-23 [14] . Indeed, STAT3 LOF mutations in patients with the autosomal-dominant hyper Immunoglobulin E (IgE) syndrome result in selective susceptibility to fungal infections by impairment of STAT3-mediated transcription of genes such as RORC and IL17 that are linked to Th17 differentiation and effector function. Indeed, deficiency of Th17 cells is a hallmark of CMC patients, including those with STAT1 GOF mutations, suggesting that STAT1 GOF mutations impair STAT3 activity [15] .
In Ebstein-Barr Virus-transformed B-cell lines and peripheral blood mononuclear cells (PBMCs) of CMCD patients with GOF STAT1, higher levels of pSTAT1 do not affect STAT3 phosphorylation and STAT3 homodimer formation, but interfere with STAT3-dependent gene transcription in response to key cytokines involved in Th17 immunity, such as IL-23 [15] . On the basis of studies of the endogenous c-Fos promoter, this reduced transcription may reflect decreased STAT3 binding. Interestingly, reduced STAT3-dependent gene transcription can be enhanced by blocking cellular histone deacetylation, which may act in this context by directly increasing the acetylation of STAT3. In contrast, blocking histone deacetylation and putatively increasing acetylation of STAT1 appears to have the opposite impact on STAT1, resulting in decreased STAT1-dependent gene transcription and the expression of transcripts that are abnormally increased in GOF STAT1 cells, such as CXCL10 and IRF1 [15] . Collectively, these findings raise the possibility that treatment with histone deacetylase inhibitors might be considered as a new approach for treating STAT1 GOF patients.
NK-cell proliferation and cytotoxic activity are also impaired in patients with STAT1-GOF mutations, which might account for their susceptibility to viral infections [13 && ]. STAT1 is a transcription factor that regulates many functions of NK cells including proliferation and IFN-g secretion in response to IL-15 and IL-2 [16] [17] [18] . In NK cells of patients with STAT1 GOF mutations, both STAT5 phosphorylation and functional response to IL-15 are impaired. This is associated with higher pSTAT1 levels in response to IL-15 stimulation, suggesting that an unbalanced ratio of STAT1/STAT5 activation results in an impaired response of NK cells to IL-15 and, secondarily, to reduced proliferation and IFN-g secretion [13 && ]. Although total immunoglobulin levels are normal in most STAT1 GOF patients, they have low percentages of both switched and unswitched memory B cells and have defective antibody responses to tetanus toxoid [3, 4, 19] . Interestingly, one GOF-STAT1 patient has been reported with hypogammaglobulinemia, CMC, delayed neurocognitive development, failure to thrive in association with Th17 deficiency and low Treg cell counts [20] . B-cell depletion in patients with GOF-STAT1 mutations is associated to increased B-cell apoptosis and overexpression of PD-L1 on the surface of naive CD4 T cells, suggesting that increased STAT1 signaling might affect B-cell survival and functions [21] .
SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION3 GAIN OF FUNCTION MUTATIONS
Like STAT1, STAT3 undergoes tyrosine phosphorylation and homodimerization or heterodimerization with other STATs in response to ligands binding their cognate receptors. In contrast to STAT1, STAT3 activation occurs downstream of many receptor families, including those of the gp130, common g chain, IL-10, IL-12/IL-23 and type I and type II IFN receptor groups [22] . Mutations in STAT3 have been associated with a variety of clinical phenotypes [23 & ]. First, somatic GOF mutations are reported in 30-40% of large granular lymphocytic (LGL) leukemias [24, 25] . Moreover, patients with germline-dominant negative LOF mutations develop AD-HIES or Job's syndrome, characterized by cutaneous and respiratory bacterial infections, mucocutaneous candidiasis, eczema, skeletal and connective tissue abnormalities, eosinophilia and high IgE levels [26] [27] [28] 
The STAT3 GOF-caused phenotype (OMIM 615952), which has been referred to as ADMIO1 (Autoimmune Disease, Multisystem, InfantileOnset 1), has early-onset autoimmune features that bear some clinical similarity to immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome. IPEX is due to LOF mutations of the X-linked gene encoding the FOXP3 transcription factor, which is essential for regulatory T-cell (T Reg ) development [32, 33] . For this reason, STAT3 GOF, along with mutations in CD25, STAT1, STAT5b and ITCH [34] [35] [36] Autoimmune manifestations included autoimmune cytopenias involving red blood cells, neutrophils and/or platelets (n ¼ 12); intestinal manifestations (n ¼ 9) [including enteropathy (n ¼ 6), celiac disease (n ¼ 2) and nonspecific colitis (n ¼ 1)]; autoimmune endocrinopathies, for example type 1 diabetes mellitus (n ¼ 6) and hypothyroidism (n ¼ 1); autoimmune lung disease (n ¼ 6) pathologically defined as lymphoid interstitial pneumonia; arthritis (n ¼ 3) and uveitis (n ¼ 1).
Lymphoproliferative symptoms included lymphadenopathy (n ¼ 11), hepatosplenomegaly (n ¼ 8), Hodgkin's lymphoma (n ¼ 1) [29 && ] and T-cell LGL leukemia (n ¼ 1) [31 & ]. As STAT3 GOF mutations frequently develop somatically in patients with such malignancy, this clinical feature suggests an oncogenic potential of ADMIO1 [24, 25] . Such suggestion is underscored by further genetic studies on the leukemic CD3
þ TCR-gd þ population, in which no loss of heterozygosity for STAT3 was observed, no genomic rearrangements were detected and novel somatic mutations were only found in a subpopulation of malignant cells [31 & ]. Notably, recurrent infections (n ¼ 11) were frequently found in these patients, including an increased risk of fungal [29 && ] and mycobacterial infections [31 & ]. Meanwhile, these last two features might possibly be explained, respectively, by reduced Th17 cells and by decreased STAT1 phosphorylation with IFN-g stimulation. Indeed, further immunological investigation revealed hypogammaglobulinemia, T-cell lymphopenia, terminal B-cell maturation arrest and a reduction in NK cells, plasmacytoid dendritic cells and isotype switched memory B cells. These data suggest that the increased risk of infections cannot only be ascribed to chronic pharmacological immune suppression, which is required in these patients [29 && ,31 & ]. Other clinical features included the following: cutaneous manifestations (n ¼ 9) such as eczema (n ¼ 6), alopecia (n ¼ 2) and nonspecific dermatitis (n ¼ 1); hepatitis (n ¼ 1); scleroderma (n ¼ 1); and low-circulating eosinophils [23 & ]. The disease is usually characterized by an early onset of symptoms (<10 years of age), although a minority of cases present in the second decade of life. Interestingly, patients with the same mutation have inconstant age of onset, as well as differences in clinical severity and organ involvement [29 && ], so it is difficult to establish a precise genotypephenotype correlation. Moreover, Milner et al. [29 && ] reported two patients with STAT3 GOF who were asymptomatic as well as a patient who only had mild symptoms (single childhood episode of lymphoproliferation and hematologic autoimmunity that resolved without sequelae), suggesting that in some cases ADMIO1 might have an incomplete penetrance.
The STAT3 protein has a similar structure to other STAT molecules, including a coiled-coil domain that is involved in dimerization/nuclear localization, a DNA-binding domain that leads to target gene binding, a linker domain, an SH2 domain that mediates STAT3 interactions through homodimers or heterodimers and a transactivation domain that promotes transcription [1 & ]. Although somatic STAT3 GOF mutations in cancer only cluster in the SH2 domain [25] , germline STAT3 GOF mutations are variously located in the coiled-coil, DNA-binding, SH2 or transactivation domain [29 && ]. ]. Functional analysis of STAT3-deficient cell lines transfected with STAT3 GOF-mutated genes has provided insight into the biological mechanisms underlying the ADMIO1 phenotype. STAT3 hyperactivity appears not to be related to hyperphosphorylation but rather increased transcriptional activity.
In support of this model, several studies show that STAT3 protein encoded by GOF mutations was not more significantly phosphorylated than the wild-type STAT3, either at baseline or in response to IL-6 stimulation [29
& ], even though a delayed dephosphorylation has been reported in some cases [29 && ] (Fig. 2) . In contrast, most studies show an augmented STAT3 transcriptional activity in cells transfected with STAT3 GOF constructs, both at baseline and after stimulation of IL-6 or IFN-a [29
. STAT3 hyperactivity may upregulate SOCS3, which, in turn, increases dephosphorylation of STAT5b [37] leading to an impairment in T Reg development and function [38] . This mechanism may account, at least in part, as to why some patients with STAT3 GOF mutation show reduced numbers of T Reg and decreased CD25 expression [29 && ]. Furthermore, SOCS3's upregulation involves also STAT1, whose phosphorylation under IFN-g stimulation is decreased [23 & ,29 && ]. This could potentially explain the mycobacterial disease observed in some patients [31 & ]. Interestingly, although STAT3 signaling plays a central role in Th17 differentiation, in part, by its upregulation of RORCgt, the Th17 master transcriptional regulator [39] , most patients with STAT3 GOF have been found to have normal or reduced numbers of Th17 cells, rather than increases [27, 28] . This suggests that the autoimmunity in STAT3 GOF patients may have a distinct mechanism other than increased Th17 immunity. Further investigations will also be of interest to define mechanisms that lead to a possible defect in lymphocyte apoptosis in ADMIO1 patients, who have an increased number of CD4 -/CD8 -(double-negative) ab-TCRþ T cells, similarly to patients with autoimmune lympho proliferative syndrome) [40, 41] .
CURRENT TREATMENT OPTIONS FOR PATIENTS WITH GAIN OF FUNCTION MUTATIONS OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION1 AND SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION3
Because of the extreme variability in the clinical spectrum of patients with STAT1-GOF mutations, the therapeutic approaches and options depend on the manifestations and course of the disease. Most of patients who present with mucocutaneous fungal infections are usually responsive to continuous treatment with oral azole antifungal drugs (i.e. fluconazole, itraconazole and voriconazole), whereas treatment of esophageal candidiasis may require intravenous antifungal therapy (i.e. fluconazole, amphotericin B and echinocandins), followed by oral azole therapy, depending on the microbial isolates [2 && ,42] . Because there is a high risk of azoleresistance in patients receiving intermittent regimens or suboptimal dosage of antifungal drugs, it is advisable to monitor serum azole concentrations to ensure that the drug levels are in the therapeutic range and to check fungal isolates for their antifungal sensitivity, particular in cases where patients are on long-term therapy. Patients with recurrent pulmonary infections have a relatively high risk to develop chronic lung disease with bronchiectasis and may benefit from daily respiratory physiotherapy and antibiotic prophylaxis, for example azithromycin [42] .
Hematopoietic stem cell transplantation (HSCT) has been utilized in STAT1 GOF patients with lifethreatening disease or CID to cure the disorder. An analysis of the outcome in an international cohort of 15 individuals has revealed significant risk of second graft failure (50%) and poor event-free STAT3   STAT3  GOF   AT3 T T T3 T T T3 3  T3 3 3  T3 T T3 3  T 
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T T T T A A S S S S S S S S S S S S S ST T T T T T TA T TA JAK JAK
Gene transcripon FIGURE 2. STAT3 signaling pathway. Germline GOF mutations of STAT3 do not usually lead to hyperphosphorylation but to increased transcriptional activity. GOF, gain-of-function; STAT3, signal transducer and activator of transcription3.
survival (10% by 100 days) [10 & ]. These results raise the question about the possible role of STAT1 hyperresponsiveness in the high risk of graft failure of patients with STAT1 GOF mutations. Control of the disease has been achieved in one child with lifethreatening autoimmune cytopenias and CMCD who received the JAK 1/2 inhibitor ruxolitinib. This treatment reduced the hyperactivation of STAT1 ex vivo by PBMCs treated with type I IFN or IFN-g, led to recovery of Th17 cells in vivo, cured the candidiasis and led to a remission of autoimmune cytopenia [43 & ]. Similarly, ruxolitinib was also effective in the treatment of alopecia in another patient with STAT1 GOF [44] . Although there are potential safety issues with chronic ruxolitinib therapy when it has been applied to other, for example, serious opportunistic infections, such as progressive multifocal leukoencephalopathy due to JC virus, these observations suggest that strategies that target STAT1 signaling might become useful options for the treatment of these patients [45, 46] .
Current treatment of ADMIO1 patients with severe autoimmune manifestations is based on the use of immunosuppressant drugs as the key therapeutic intervention [23 & ]. However, HSCT also has been performed in two patients: in one case, it was curative, with complete resolution of the previously severe autoimmune enteropathy; the other patient unfortunately died of severe graft-versus-host disease and disseminated adenovirus infection [29 && ]. Milner et al. [29 && ] administered tocilizumab (anti-IL-6 receptor humanized monoclonal antibody) to a patient who presented arthritis and scleroderma-like skin changes resistant to tumor necrosis factor alpha and IL-1 antagonist therapies and to B-cell depletion, and this led to a dramatic improvement in arthritis and skin lesions. Such therapeutic success might be explained by the fact that IL-6 is one of the primary cytokines that utilizes STAT3 for signal transduction [29 && ,47] . Finally, new drugs targeting STAT3 pathway have become available, some of which are in clinical trials [48, 49] , and this approach might constitute an effective therapeutic option for ADMIO1 patients.
CONCLUSION
Patients with STAT1 or STAT3 GOF mutations display distinct clinical manifestations, but patients with severe autoimmunity or severe/invasive infections may require similar treatment approaches. HSCT has been utilized as curative option in both STAT1 and STAT3 GOF patients when disease was severe or life-threatening, but has been associated with risk of graft failure and poor survival. In addition, availability of drugs that target STAT1 and STAT3 signaling pathways has the potential for therapy directed at the specific disease-causing abnormality in this group of disorders.
